Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 863,700 shares, an increase of 95.2% from the February 29th total of 442,400 shares. Currently, 6.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VINC. Tejara Capital Ltd acquired a new position in shares of Vincerx Pharma during the fourth quarter worth $317,000. Millennium Management LLC lifted its position in shares of Vincerx Pharma by 562.4% during the second quarter. Millennium Management LLC now owns 306,598 shares of the company’s stock worth $405,000 after purchasing an additional 260,310 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Vincerx Pharma by 21.0% during the first quarter. Affinity Asset Advisors LLC now owns 1,374,098 shares of the company’s stock worth $5,496,000 after purchasing an additional 238,733 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Vincerx Pharma by 120.5% during the second quarter. Renaissance Technologies LLC now owns 312,522 shares of the company’s stock worth $413,000 after purchasing an additional 170,778 shares in the last quarter. Finally, ExodusPoint Capital Management LP raised its holdings in Vincerx Pharma by 56.1% in the first quarter. ExodusPoint Capital Management LP now owns 391,748 shares of the company’s stock valued at $407,000 after acquiring an additional 140,753 shares in the last quarter. 44.02% of the stock is owned by institutional investors and hedge funds.

Vincerx Pharma Trading Up 18.4 %

VINC opened at $6.06 on Thursday. The company has a 50 day moving average of $3.50 and a two-hundred day moving average of $1.82. Vincerx Pharma has a 52-week low of $0.61 and a 52-week high of $9.37.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.